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Abstract Evidence is rapidly emerging which suggests that 
uncoupling protein 2 (UCP2), by virtue of its ubiquitous 
expression, may be important for determining basal metabolic 
rate. To assess the functional modulation of UCP2 gene 
expression in relation to body weight control, we examined the 
effects of hyperthyroid state induced by chronic treatment with 
triiodothyronine (T3) on UCP2 mRNA expression in male rats. 
Daily subcutaneous injection of T3 (37 pmol/100 g body weight) 
for 7 days increased UCP2 mRNA expression in brown adipose 
tissue (BAT), white adipose tissue (WAT) and the soleus muscle 
1.6-, 1.6- and 1.7-fold compared to the controls, respectively, and 
increased UCP1 mRNA expression in BAT 1.2-fold. In contrast, 
the same treatment with T3 decreased both ob mRNA expression 
in WAT and plasma leptin level 0.5-fold for each. The present 
results suggest that T3 may directly increase UCP2 expression 
independently of leptin action. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Uncoupling protein (UCP) is a unique protein located in 
the inner mitochondrial membrane and its main function is to 
allow proton re-entry into the mitochondrial matrix [1]. This 
proton dissipates energy as heat instead of being used for 
adenosine triphosphate production [1]. It is well known that 
UCP plays an important role in the regulation of energy ex-
penditure in mammals [2]. 
UCP1, by virtue of its unique expression in brown adipose 
tissue (BAT) and its cyclic adenosine monophosphate-respon-
sive element, primarily mediates cold exposure-induced ther-
mogenesis for the purpose of defending body temperature. 
This thermogenesis due to UCP1 is controlled by activity of 
efferent sympathetic nerves to pVadrenergic receptors (pVAR) 
of BAT [3,4]. There is a growing body of evidence that thy-
roid hormone is one of the essential factors affecting UCP1 
activity. Sensitivity of P3-AR and expression of UCP1 mRNA 
in response to cold were lower in hypothyroid rats [5]. These 
defects were fully corrected by replacement of triiodothyro-
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nine (T3) [5]. UCP1 mRNA in BAT of rat fetuses with hyper-
thyroidism increased 1.2-fold compared to euthyroid controls 
[6]. Thus, UCP1 in BAT is believed to be a major thermogenic 
effector and its activity is modulated at least in part by thy-
roid hormone in rodents [7]. In adult humans, however, the 
limited BAT cannot explain the increased energy expenditure 
during hyperthyroidism attributable to enhanced expression 
of UCP1 mRNA. BAT in humans proliferates to express 
UCP1 [8] only under conditions of prolonged cold exposure 
or catecholamine producing tumors. 
A novel member of the UCP family, termed UCP2, has 
been cloned recently [9]. Evidence to date indicates that the 
product of the UCP2 gene is crucial for mammalian thermo-
genesis similarly to UCP1 because of its high degree of se-
quence similarity (55-60%) to UCP1 [9]. UCP2 is widely ex-
pressed in human and rodent tissues [9-12], unlike UCP1, 
which is expressed uniquely in BAT. The ubiquitous expres-
sion of UCP2 suggests that the protein may be important for 
determining basal metabolic rate, and possibly regulating 
body weight in mammals including humans. Thyroid hor-
mone is known to increase the basal metabolic rate in human 
[13]. Taken together, these findings led to a hypothesis based 
on possible mechanisms that increased basal metabolic rate 
during hyperthyroidism may depend on increases not only 
in UCP1 but also in UCP2 mRNA expression. Therefore, 
thyroid hormone may regulate the expression of both pro-
teins. 
To test this hypothesis, hyperthyroid rats treated with 
chronic administration of T3 were examined for UCP2 
mRNA expression in BAT, white adipose tissue (WAT) and 
skeletal muscle. Since expression of UCP2 mRNA is directly 
enhanced by plasma leptin concentration [14], expression of 
the ob gene and plasma leptin levels were also examined. 
Possible interactions of thyroid hormone with UCP2 expres-
sion and leptin secretion are discussed. 
2. Materials and methods 
2.1. Experimental procedure 
Mature male Wistar King A rats (Seac Yoshitomi Ltd., Fukuoka, 
Japan), 259-275 g at 8-9 weeks of age, were used. They were housed 
in a soundproof room illuminated daily from 7.00 to 19.00 h (a 
12:12 h light:dark cycle) with temperature at 21 ± 1°C, and humidity 
55 ± 5%. The rats were allowed free access to tap water and standard 
pellet rat chow (CE-2, CLEA Japan Ltd., Tokyo, Japan). Body weight 
was measured daily at 9.00 h. Matched on the basis of body weight on 
the first injection day, eight rats were equally divided into T3-treated 
(T3) and saline-treated control groups. The solution of T3 (Aldrich 
Chemical Co., Milwaukee, USA) was freshly dissolved in physiolog-
ical saline at a concentration of 0.37 mM. To increase plasma T3 level 
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and render animals hyperthyroid, rats in the T3 group were daily 
injected subcutaneously with T3 solution at a dose of 37 pmol/100 g 
body weight in a volume of 0.1 ml solution for 7 days. The injection 
procedure of the controls was same as that of the T3 group. The T3 
group was deprived of T3 treatment for 24 h before blood sampling. 
After decapitation, BAT, the epididymal fat tissue (WAT) and the 
soleus muscle were surgically removed and immediately frozen in 
liquid nitrogen, then stored at —80°C until RNA extraction. 
2.2. Measurement of plasma Ts, Tj, TSH and leptin concentration 
Plasma samples were collected at 12.00 h immediately before and 
on the 7th day after the treatment following an overnight fast. The 
sample was immediately frozen at —20°C. T3, thyroxine (T4) and 
thyroid stimulating hormone (TSH) were measured with a commer-
cially available RIA kit (T3 and TSH RIA beads, Dainabot, Tokyo, 
Japan; M-T4 RIA Chiron 2, Chiron, California, USA). Plasma leptin 
was measured with a commercially available kit (sandwich enzyme 
immunoassay, Immune Biological Laboratory, Gunma, Japan). The 
lowest limit of detection for leptin was 200 pg/ml. 
2.3. Northern blot analysis 
Total cellular RNAs were prepared from various rat tissues with the 
use of Isogen (Nippon Gene, Toyama, Japan) according to the man-
ufacturer's protocol. Total RNAs (20 ug/lane) of samples from the 
BAT, WAT and the skeletal muscle were electrophoresed on 1.2% 
formaldehyde-agarose gel and the separated RNAs were transferred 
onto a Biodyne B membrane (Pall Canada Ltd., Mississauga, Ont., 
Canada) in 20XSSC by capillary blotting [15] and immobilized by 
exposure to ultraviolet light (0.80 J). Prehybridization and hybridiza-
tion were carried out according to the method described by Yang et 
al. [16], except that 32P-labeled rat UCP2 cDNA fragment was used as 
a probe (unpublished data). Membranes were washed under high 
stringency conditions [16]. After washing the membranes, the hybrid-
ization signals were analyzed with a BlO-image analyzer BAS 2000 
(Fuji Film Institution, Tokyo, Japan). The membranes were stripped 
by exposure to boiling 0.1% SDS and rehybridized with a ribosomal 
RNA (rRNA) that was used to quantify the amounts of RNA species 
on the blots. 
All data are expressed as the mean ± S.D. The statistical significance 
of differences was assessed by the unpaired /-test. The animals were 
used in accordance with the Oita Medical University Guidelines based 
on the NIH Guide for the Care and Use of Laboratory Animals. 
3. Results 
3.1. Effects of chronic Ts treatment on plasma concentrations 
of Ts, T/H TSH and body weight 
Table 1 shows changes in plasma levels of T3, T4 and TSH, 
and body weight after daily T3 injection for 7 days. Plasma T3 
level significantly increased in the T3 group compared with 
that in the control group (P< 0.001). Plasma T4 level de-
creased more in the T3 group than in the controls 
(P< 0.001). TSH in these groups became undetectable after 
7-day treatment with T3. The body weight before the treat-
ment did not differ between the two groups. Body weight in 
the T3 group decreased after the 7-day T3 treatment, in con-
trast to the increase in body weight of the controls during the 
same period. 
3.2. Effects of chronic Ts treatment on UCP2 mRNA 
expression in BAT, WAT and skeletal muscle, and 
on UCP1 mRNA expression in BAT 
Northern blot analyses of UCP2 mRNA in BAT, WAT and 
the skeletal muscle, and of UCP1 mRNA in BAT are shown 
in Fig. 1. The T3 treatment increased UCP2 mRNA expres-
sion in all those tissues 1.6-, 1.6-, and 1.7-fold, respectively, 
compared to the controls ( P < 0.001 for each). UCP2 mRNA 
in the heart also increased 2.3-fold in the T3 group 
(0.05 ±0.002, mRNA/rRNA a.u.) compared to the controls 
(0.022±0.006, mRNA/rRNA a.u.; P<0.001 vs. T3 group) 
(data not shown in Fig. 1). The expression of UCP1 mRNA 
in BAT increased 1.2-fold in the T3 group compared with to 
the controls (P<0.01). 
3.3. Effects of chronic Ts treatment on ob mRNA in WAT and 
plasma leptin concentration 
As shown in Fig. 2A, chronic T3 treatment decreased ob 
mRNA expression in WAT 0.5-fold compared with the con-
trols (P< 0.001). Plasma leptin concentration concomitantly 
decreased 0.5-fold in the T3 group, compared to the controls 
(P< 0.001) (Fig. 2B). 
4. Discussion 
The present study demonstrates that hyperthyroid state in-
duced by 7-day treatment with T3 increased rat mRNA ex-
pression of not only BAT UCP1 but also UCP2 in BAT, 
WAT, skeletal muscle and the heart. These findings raise a 
question as to whether the enhanced expression of UCP2 
induced by chronic treatment with T3 may be the result of a 
direct or an indirect effect. It is suggested that there are pos-
sible interactions between T3 and leptin and sympathetic nerve 
activity. 
Overexpression of leptin per se has been shown to increase 
UCP2 mRNA in lean Zucker rats (+/+) [14]. If leptin is a 
mediator of UCP2 under the hyperthyroidism in the present 
study, T3 treatment should up-regulate ob gene expression. In 
contrast, the present data show decreases in ob gene expres-
sion and plasma leptin concentration. This decrease is consis-
tent with the previous finding that prolonged administration 
of T3 decreased body weight and fat mass, resulting in a 
reduction of leptin secretion [17]. Together with the data pre-
sented here, the foregoing findings seem to demonstrate that 
leptin is not the mediator of T3-induced increase in UCP2 
expression. 
BAT is known to be richly innervated by sympathetic effer-
ent nerves. Hyperactivity of sympathetic nerves in hyperthy-
roidism enhances UCP1 expression in BAT. In this context, it 
is postulated that pVadrenergic activity in hyperthyroidism 
may be one of the UCP2 regulators similar to UCP1 in hyper-
Table 1 
Changes in plasma concentration of T3, T4 and TSH and body weight before and after chronic treatment with T3 
Controls 
T3-treated 
T3 (ng/ml) 
0.5 ±0.04 
7.0 ±0.9** 
T4 (ng/ml) 
3.0 ±0.7 
1.0>** 
TSH (uU/ml) 
ND 
ND 
Body weight (g) 
Before 
263.3 ±4.9 
265.6 ±7.6 
After 
274.8 ±3.8 
247.1 ± 8 ^ 
Values are the mean ± S.D. of n treated rats. ND, not detectable. Before/after, before/after the 7-day T3 treatment. T3-treated, the group injected 
with daily subcutaneous T3 at a dose of 37 mmol/100 g body weight. 
tP<0.05 vs. the corresponding initial value. **p< 0.001 vs. the corresponding controls. 
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Fig. 1. The effects of T3 on UCP2 mRNA expression in the BAT, WAT and skeletal muscle, and on UCPl mRNA expression in BAT. North-
ern blot analysis of UCP2 was performed in total RNA (20 |ig/lane) of the samples from BAT, WAT and skeletal muscle, and that of UCPl 
from BAT. To quantify amounts of mRNAs from those tissues, the blots were reprobed with rRNA. Values and vertical bars, mean ± S.D. 
(« = 4). a.u., arbitrary units. **P<0.001, *P<0.01 vs. the corresponding controls. 
thyroidism. Evidence to date, however, shows that this is still 
not clear, because expression of UCP2 can be significantly 
changed in catecholamine-null mice [18], and the effect of 
p3-adrenergic activity on UCP2 expression is reported incon-
sistently by investigators [9,19]. 
A recent study has demonstrated that fasting increases 
U C P 2 m R N A expression in skeletal muscle [19]. In the 
present study, hyperthyroidism reduced body weight and in-
creased U C P 2 expression in skeletal muscle. These findings 
indicate the possibility that body weight loss may cause the 
elevation of UCP2 expression. However, the assumption that 
the elevated U C P 2 expression may be caused by the weight 
loss per se can be negated for the following reasons. (1) Body 
weight loss due to fasting did not affect U C P 2 expression in 
the heart or BAT [19]. Thus, weight reduction does not nec-
essarily reflect changes in U C P 2 m R N A expression in all bod-
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Fig. 2. The effects of T3 on ob gene mRNA expression in the WAT (A) and plasma leptin concentration (B). Northern blot analysis of ob 
gene was performed in total RNAs (20 ug/lane) of WAT samples. To quantify amounts of mRNA from WAT, the blots were reprobed with 
rRNA. Values and vertical bars, mean± S.D. (11 = 4). a.u., arbitrary units. **P< 0.001, *P<0.01 vs. the control. 
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ily tissues. (2) In the present study, body weight reduction 
following hyperthyroidism increased U C P 2 expression even 
in the heart and BAT. 
Evidence to date substantially suggests that T3 may directly 
up-regulate U C P 2 m R N A expression in BAT, WAT, skeletal 
muscle and the heart. The present study provides evidence 
that thyroid hormone is a potent activator of UCP2. The 
relation between thyroid hormone and U C P 2 is indispensable 
for understanding the physiological regulation mechanisms of 
energy balance and metabolism. The present results may help 
to explain the elevated energy expenditure in hyperthyroidism. 
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